Sun Pharmaceutical Industries Ltd banner

Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 795.4 INR 2.4% Market Closed
Market Cap: ₹4.3T

Intrinsic Value

The intrinsic value of one SUNPHARMA stock under the Base Case scenario is 1 170.27 INR. Compared to the current market price of 1 795.4 INR, Sun Pharmaceutical Industries Ltd is Overvalued by 35%.

SUNPHARMA Intrinsic Value
1 170.27 INR
Overvaluation 35%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Get notified when the price drop
Track Buy Zone
20% below Intrinsic Value ₹936.21
Get notified when the price drops into your buy zone
Current Price ₹1 795.4
Intrinsic Value ₹1 170.27
Margin of Safety 20% ₹936.21
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about SUNPHARMA?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SUNPHARMA valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Sun Pharmaceutical Industries Ltd.

Explain Valuation
Alternatives to SUNPHARMA

Wall St
Price Targets

Dividends

Shareholder Yield

Competitive Landscape

Ownership

SUNPHARMA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SUNPHARMA stock?

The intrinsic value of one SUNPHARMA stock under the Base Case scenario is 1 170.27 INR.

Is SUNPHARMA stock undervalued or overvalued?

Compared to the current market price of 1 795.4 INR, Sun Pharmaceutical Industries Ltd is Overvalued by 35%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett